Passage Bio, Inc. Form 8-K Summary
Business context and reporting period
Passage Bio filed a Current Report on Form 8-K dated May 5, 2020, reporting entry into an amended and restated sponsored research, collaboration and licensing agreement with The Trustees of the University of Pennsylvania (“Penn”). The agreement supersedes the parties’ September 18, 2018 agreement, as amended.
Key financial and operating terms
- Passage Bio committed to fund Penn discovery research for five years beginning May 5, 2020.
- The funding commitment is $5.0 million per year, payable in quarterly installments of $1.3 million.
- The agreement provides the company with rights arising from the funded discovery research and license rights to patents covering a new gene therapy technology developed by Penn.
- The company received eleven remaining options, increased from six, to initiate additional licensed programs for rare, monogenic central nervous system indications.
- The option exercise window was extended by three years; the eleven options may be exercised during the five years following May 5, 2020.
- Exercise of an option would require a non-refundable upfront payment of $1.0 million per product indication.
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other periodic financial statement metrics.
Material changes versus the prior agreement
- Annual discovery-research funding was established at $5.0 million, with quarterly payments of $1.3 million.
- Available program options increased from six to eleven.
- The option exercise period was extended by three years.
- The company obtained additional patent license rights relating to a new Penn-developed gene therapy technology.
Outlook, risks, contingencies, and unusual items
The agreement creates a significant five-year research funding obligation totaling $25.0 million based on the stated annual commitment, subject to the agreement’s terms. Additional potential cash obligations include $1.0 million in non-refundable upfront fees for each option exercised. The filing does not describe the company’s available liquidity, ability to fund these commitments, development timelines, regulatory outcomes, or commercial prospects.
The complete Penn Expansion Agreement was not included in the provided filing text; the company stated that it intended to file the agreement as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending June 30, 2020.
Important facts for investors to verify
- Review the definitive Penn Expansion Agreement and its detailed payment, termination, milestone, licensing, and intellectual-property provisions.
- Verify the company’s cash balance, liquidity runway, and funding sources relative to the five-year $25.0 million research commitment.
- Assess the probability, timing, and expected costs of exercising any of the eleven program options.
- Review subsequent filings for accounting treatment of the commitment and any additional obligations or amendments.
- Evaluate whether the newly licensed technology and discovery programs have produced material clinical, regulatory, or commercial developments.